picibanil and Retroperitoneal-Neoplasms

Primary retroperitoneal tumors are reported to account for 0.2% of all malignancies. Furthermore, 10-20% of all primary retroperitoneal tumors are liposarcomas. Up to 1989, 213 cases of retroperitoneal liposarcoma have been reported in the Japanese literature to our knowledge. Mixed type liposarcomas were rare, and composed 13.8% of all retroperitoneal liposarcomas in this series. We described here a case of retroperitoneal mixed type liposarcoma. A 50-year-old man was admitted to our department with a mass in the left abdomen. Computed tomography and aortography revealed a huge and hypovascular tumor in the retroperitoneal cavity, not containing fat tissue. It was diagnosed as a retroperitoneal tumor and treated surgically. The tumor and the left kidney were encapsulated and could be removed en bloc. The size and weight of the tumor were 28 x 18 x 12 cm and 3,100 g, respectively. Histological examination of the mass proved it to be a mixed type liposarcoma. He was administered OK-432 as adjuvant therapy. After 11 months, bone metastasis to the vertebra appeared. Moreover, lung metastasis also occurred and he died of the disease 15 months after the operation.

Topics: Combined Modality Therapy; Humans; Liposarcoma; Male; Middle Aged; Neoplasm Metastasis; Picibanil; Retroperitoneal Neoplasms; Tomography, X-Ray Computed; Urography

Retroperitoneal lymphangioma is extremely rare. Although these neoplasms are benign, they can grow progressively with subsequent compression and infiltration of the adjacent structures. Surgical excision is demanding when the lesion surrounds vital structures and it is generally fraught with a high recurrence and morbidity rate. We report the case of a huge retroperitoneal lymphangioma in a newborn treated successfully with intracystic injection of OK-432.

Topics: Antineoplastic Agents; Humans; Infant, Newborn; Injections; Lymphangioma; Male; Picibanil; Retroperitoneal Neoplasms; Sclerotherapy

Retroperitoneal lymphangioma is extremely rare. It may obstruct or invade surrounding vital organs, which may result in lethal effects to the host. Although surgical excision has been suggested as the first choice for treatment, complete extirpation is often impossible. Moreover, the rates of postoperative morbidity and disease recurrence remain high. We report a case of a huge retroperitoneal lymphangioma extending to the flank and scrotum that was successfully treated by intralesional OK-432 sclerotherapy without any serious complications.

Topics: Abdominal Wall; Antineoplastic Agents; Genital Neoplasms, Male; Humans; Infant, Newborn; Injections, Intralesional; Lymphangioma; Male; Picibanil; Radiography; Retroperitoneal Neoplasms; Sclerotherapy; Scrotum

Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Gastrointestinal Neoplasms; Humans; Picibanil; Radiography, Abdominal; Retroperitoneal Neoplasms; Sarcoma; Tomography, X-Ray Computed

Nine patients with cystic hygroma were treated with a new sclerosing therapy consisting of intracystic injection of OK-432 (group A Streptococcus pyogenes of human origin). Favourable results including complete regression in eight patients and marked regression in one were observed within 2-3 months without serious side-effects except for fever of 2-3 days' duration and local inflammatory reaction lasting for 3-4 days. Local inflammatory reaction did not cause any damage to the overlying skin and did not lead to scar formation.

Topics: Abdominal Neoplasms; Adolescent; Biological Products; Child, Preschool; Female; Head and Neck Neoplasms; Humans; Infant; Lymphangioma; Male; Picibanil; Retroperitoneal Neoplasms; Sclerosing Solutions